INTRODUCTION
helical filament tau protein-rich neurofibrillary tangles (NFT) [5] . Both types of lesions have been linked to AD dementia, MCI, and cognitive decline. There is also evidence that NFT mediates the association between amyloid plaques and clinical manifestations of AD [6] . While the exact physiology through which NFT and amyloid-beta plaques influence AD pathogenesis remains somewhat unclear, the presence of such deposits among those afflicted with AD is typically associated with much steeper trajectories of cognitive deficit accumulation with age [7, 8] . Cognition is not a unitary process but is composed of several dissociable cognitive systems, such as episodic memory the clinical hallmark of AD dementia.
Epigenetic alterations, such as DNA methylation (DNAm), have been linked to the both AD pathology [9] and cognitive aging in the absence of AD dementia [10] . DNAm refers to the addition of a methyl group to a cytosine nucleotide at cytosine-phosphate-guanine (CpG) sites. Hyper-or hypo methylation of sites can change over time, as a function of genes and environment, and have implications for gene expression via alterations in chromatin structure. We recently developed a highly accurate molecular biomarker of aging based on DNA methylation (DNAm) levels [11] , known as "epigenetic clock", which can be used to measure the age of human cells, tissues, and organs. Given that aging is associated with a normal loss in cognitive ability as well as the rapidly increasing susceptibility to AD, an aging biomarker based on DNAm could account for between-person differences in either the rate of cognitive aging among non-demented individuals or the rate of disease progression among those with AD. As a result, the goals of our study were to 1) examine the association between DNAm age and AD neuropathology, 2) test whether DNAm age relates to AD dementia status and measures of cognitive functioning, 3) determine if differences in DNAm age reflect cognitive decline in persons with or with ADdementia, 4) examine whether neuropathology underlies the association between higher DNAm age and worse cognitive functioning. We hypothesize that participants who have higher levels of neuropathology, lower cognitive functioning, and/or who are diagnosed with AD will have higher DNAm age in PFC samples at deathsignifying that their brains are biologically older. We also hypothesize that neuropathology will mediate the association between DNAm age and cognition.
RESULTS

Study Sample
Our analytic sample included Caucasian subjects from the Religious Order Study (ROS) and the Rush Memory and Aging Project (MAP) [12, 13] . Both are longitudinal community based cohort studies of aging and dementia. The majority of participants in both studies are 75-80 years old at baseline with no known dementia. All participants agree to organ donation at death.
Participants sign and informed consent, repository consent, and Anatomical Gift Act. The studies were approved by the Institutional Review Board of Rush University Medical Center. Inclusion in the studies requires participants to consent to undergoing annual clinical evaluations as well as postmortem organ donation. The ROS sample includes Catholic priests, nuns, and brothers from across the United States, whereas the MAP sample includes a more general community based population from northeastern Illinois. For our analysis, we excluded subjects with missing DNAm age, or who were diagnosed with dementias other than AD leaving us with 700 Caucasian subjects. Participants were administered annual structured interviews and a battery of cognitive tests such as episodic memory (EM), working memory (WM), and semantic memory (SM), perceptual orientation (PO), and perceptual speed (PS). Tests were averaged to yield a measure of global cognitive functioning (GCF). Neuropathological assessments were carried out postmortem as described in Methods.
Sample characteristics
As shown in Table 1 
Epigenetic age relates to neuropathological variables
We estimated the epigenetic age (also known as DNAm age) of each brain samples by averaging the DNAm levels of 353 CpGs as described in Methods and [11] . DNAm age (in units of years) estimates the number of years that passed since birth. DNAm age was highly correlated with chronological age at time of death across all samples (correlation r=0.67, Figure 1A ). We defined a measure of epigenetic age acceleration as residual resulting from regressing DNAm age on chronological age and sex. Thus, a positive value of age acceleration indicates that the epigenetic age is higher than expected based on chronological age and sex. Our study addresses the hypothesis that epigenetic age acceleration (that measures deviations between DNAm age and chronological age) captures aspects of the biological age of brain tissue. We test this hypothesis by relating epigenetic age acceleration to various measures of neuropathology and cognitive functioning.
Results from biweight midcorrelation showed that epigenetic age acceleration is associated with several postmortem neuropathological indices. Epigenetic age acceleration had a correlation of 0.12 with diffuse plaques (p=0.0015, Figure 1B ,C), 0.11 with neuritic plaques (p=0.0036, Figure 1D ,E), and 0.019 with amyloid load (p=0.016, Figure 1H ,I). Further, it showed a marginally significant association with neurofibrillary tangle status (p=0.053 in Figure 1G ) when the latter was defined by dichotomizing the NFT variable by its median value. These associations were also examined using multivariate models (Table 2) , adjusting for age at death, sex, and study (ROS vs MAP), and again, we found positive associations between DNAm age and neuritic plaques (β=0.45, p=0.004), diffuse plaques 
DNAm age, cognitive functioning and AD status
As shown in Table 3 , we used linear models, adjusting standard errors to account for multiple observations, to examine whether postmortem estimates of DNAm age were associated with GCF, EM, WM, SM, PO, PS, and/or AD status. We found associations between DNAm age and both GCF and EM, the clinical hallmark of AD. For instance, results showed that a one unit decrease in GCF was associated with about a one third of a year increase in DNAm age (β = -0.34, P = 0.019), while a one unit decrease in EM was also associated with about a one third of a year increase in DNAm age (β = -0.30, P = 0.009). By contrast, we did not find a relationship between DNAm age and WM (β = -0.16, P = 0.172), SM (β = -0.21, P = 0.072), PO (β = -0.10, P = 0.270), or PS (β = -0.13, P = 0.191). We also examined whether AD dementia status was associated with higher DNAm age. Results showed a moderate, but nonsignificant association (β = 0.38, P = 0.103). Using linear models, we then examined the association between DNAm age and cognitive functioning by AD dementia status (Table 4 ). Overall, we found no association between DNAm age and any of the cognitive functioning measures among participants without AD dementia which might reflect the relatively low variance of cognitive measures among controls. However, among participants with AD dementia, GCF, EM, and WM were all associated with DNAm age. Results showed that for persons who developed AD dementia, every one unit decrease in GCF was associated with a half a year increase in DNAm (β = -0.50, P = 0.009). Similarly, for persons who developed AD dementia, every one unit decrease in EM or WM was associated with about a 0.4 year increase in DNAm (EM: β = -0.41, P = 0.009; WM: β = -0.40, P = 0.011).
Mediation analysis involving neuropathological variables and cognitive scores
Using multivariate linear models, with DNAm age as the dependent variable and adjusting for study (ROS vs MAP), age at clinical assessment, age at death, and sex, we examined whether neuropathological measures accounted for the association between worse cognitive functioning (GCF, EM) and higher DNAm age ( Table 5 and Table 6 ). All models were run on n=695 participants who had complete neuropathology data. Standard errors were adjusted to account for repeat cognitive measures. For each cognitive measure, seven models were run. The first model shows the association between the cognitive measure and DNAm age, after adjusting for covariates. We find that (as reported previously), GCF and EM were inversely associated with DNAm age (GCF: β=-0.336, P=0.020; EM: β=-0.286, P=0.012). Model 2, is similar to model 1, but includes the addition of amyloid load, to examine whether it alters the association between cognitive functioning and DNAm age. We find that amyloid load is significantly associated with DNAm age. 
Heritability and genetic correlation analysis
We estimated the heritability of epigenetic age accelera-tion using the GCTA software [14, 15] from SNP markers measured on the same subjects. We find that epigenetic age acceleration in DLPFC is highly heritable (h 2 =0.41, Table 7 ), which is similar to heritability estimate reported for blood [11, 16] .
We find that diffuse plaques are highly heritable (h 2 =0.38, Table 7 ) and have a significant genetic correlation with epigenetic age acceleration (r=0.24, p=0.010, Table 7 ). Neuritic plaques also exhibit a significant genetic correlation with epigenetic age acceleration (r=0.78, p=0.014) but the result needs to be interpreted with caution since neuritic plaques are at best weakly heritable (h 2 =0.05). We also find a suggestive genetic correlation with working memory at the last assessment (r=-0.35, p=0.065) but working memory is only weakly heritable (h 2 =0.07). 
DISCUSSION
Overall, we found that postmortem DNAm age in DLPFC was associated with neuropathological variables (Figure 1 and Table 2 ) and with pre-mortem measures of cognitive decline, after adjusting for chronological age, sex, and other possible confounders (Tables 3 and 4 ). Our mediation analysis (Tables 5-6) suggests that a proportion (up to 66%) of the association between DNAm age and measures of cognitive function is mediated by neuropathological measures. Our genetic analysis (Table 7) indicates that pleiotropic genetic loci affect epigenetic age acceleration, neuropathological variables, and cognitive traits.
The association between cognitive function and DNAm age is consistent with previous work showing that general cognitive ability-defined as a composite score for six cognitive function tests comprising working memory, non-verbal reasoning, constructional ability, and processing speed-was associated with DNAm age in pre-mortem blood samples [17] . However, previous work has not examined the role of neuropathology or AD dementia in the association between DNAm age and cognitive decline. Our study showed that about half of the association between DNAm age and cognition was accounted for by variations in neuropathological variables. For instance, we found that worse GCF and EM was associated with higher DNAm age; however, this association was significantly reduced or eliminated after adjusting for amyloid load or neuritic plaques.
Previous studies have shown that there is little or no age effect on many cognitive domains after accounting for common neuropathologies [18] . The extended preclinical phase of dementia is typically characterized by an accumulation of neuropathology underlying cognitive decline, and as such, pathologies have been shown to relate to decline across the entire continuum, from normal, to MCI, to dementia [19, 20] . Nevertheless, declines in cognitive functioning have been shown to be significantly steeper among those with AD [21] [22] [23] [24] . In contrast to those with nonpathological cognitive aging, the more drastic cognitive decline associated with AD is thought to reflect ADmediated neuronal injury, larger decreases in brain volume, functional disconnection between PFC and the hippocampus, and dramatic increases in ventricle size [3, 25] .
While our results showed that DNAm age was associated with cognitive decline among persons with a clinical diagnosis of AD, we did not find an association between AD dementia status and DNAm age. One poten-tial explanation for the lack of association between AD dementia status and DNAm age is that the clinical diagnosis AD is only an incomplete measure of the underlying neuropathology such as the accumulation of amyloid-beta plaques and NFT. For this reason, AD reflects a heterogeneous group, which is why the severity of AD (as estimated by cognitive decline or neuropathology) may be more strongly associated with DNAm age than AD dementia status alone. Among our participants, we found that both the between-person and within-person variance in GCF and EM change was much higher for those with AD versus those without AD dementia (Table 8 ), suggesting that 1) the AD group may be far more heterogeneous in regards to The GCTA software was used to estimate the heritability (first two columns) and the genetic correlations with epigenetic age acceleration (last two columns).
www.impactaging.com neurocognitive decline, and 2) experience far more cognitive aging changes. Additionally, this interpretation is supported by our analysis of neuropathological variables, for which we found strong associations between DNAm age and all five measures (amyloid load, neuritic plaques, diffuse plaques, NFT, and overall tangle score). Additionally, results from step-wise models showed that neuropathological variables, especially amyloid load and neuritic plaques, may explain the association between DNAm age and cognitive functioning. This suggests that increased DNAm age may influence changes in the regulation of amyloid proteins, contributing to AD neuropathology, and thus manifesting as steeper cognitive declines [26] .
Finally, our genetic analysis showed that DNAm age, neuropathology, and cognitive decline may be pleiotropic, which could reflect mediation among these factors. For instance, alleles could be associated with faster cognitive decline via acceleration of the biological aging process, which in turn leads to a faster accumulation of neuropathology (Figure 2A) . Another alternative is that physiological consequences associated with neuropathological accumulation could influence both biological brain aging and cognitive decline, simultaneously ( Figure 2B ). Finally, loci could pleiotropically influence both neuropathology and biological aging, independently, with no causal pathway between them ( Figure 2C ). In moving forward, examina- www.impactaging.com tion of these pathways will be important for facilitating our understanding of brain aging and neurodegenerative disease.
There are limitations to this study. First, DNAm age was only measured postmortem, which prevented us from determining if it was predictive of AD status or cognitive decline. Furthermore, DNAm age changes with time, yet in our sample it was only measured at a single time-point. For that reason we were unable to examine if larger changes in DLPFC DNAm age were associated with steeper cognitive decline or AD. Nevertheless, our study was strengthened by the inclusion of neuropathological variables, longitudinal measurements of multiple cognitive functioning domains, measurement of DNAm age in DLPFC rather than whole blood, and availability of postmortem data for neuropathologic indices.
Overall, our study shows that epigenetic aging in DLPFC is associated with the severity of cognitive decline as well as neuropathological hallmarks of AD.
These results strongly suggests that the epigenetic clock lend itself as a molecular biomarker of brain age.
METHODS
Study sample. Our analytic sample included 700 non-Latino white subjects from the Religious Order Study (ROS) and the Rush Memory and Aging Project (MAP) [12, 13] . Both are longitudinal community based cohort studies of aging and dementia. The majority of participants in both studies are 75-80 years old at baseline with no known dementia. Inclusion in the studies requires participants to consent to undergoing annual clinical evaluations as well as postmortem organ donation. The ROS sample includes Catholic priests, nuns, and brothers from across the United States, whereas the MAP sample includes a more general community based population from northeastern Illinois. For our analysis, excluded subjects included those with missing DNAm age, or who were diagnosed with dementias other than AD.
Clinical evaluations. Participants were administered annual structured interviews to assess cognitive functioning. These included tests for EM (immediate recall (word list), delayed recall (word list), word recognition (word list), immediate recall (East Boston story), delayed recall (East Boston story), logical memory immediate recall, logical memory delayed recall), WM (digits forward, digits backward, digit ordering), SM (Boston naming, category fluency, reading test), PO (line orientation, progressive matrices), and PS (symbol digits modality-oral, number comparison, stroop color naming, stroop color reading). For each domain, composite measures were calculated as the average across tests. Before taking the average, each cognitive test was converted to a z-score (with mean of zero and standard deviation of 1). Finally, GCF is meant to represent overall cognitive functioning. At each wave it was estimated as the average across zscores from the 19 cognitive tests for EM, WM, SM, PO, and PS.
Neuropathological examination. Upon participants' death, brains were extracted, weighed, sectioned into 1 cm-thick coronal slabs, and stored. Neuropathological indices were examined in order to diagnose cognitive pathologies such as AD, Lewy Body diseases, and cerebrovascular disease [27] . Modified Bielschowsky silver stain was used to identify AD pathology based on NIA-Reagan and modified CERAD criteria. Global AD pathologic burden was estimated by averaging standardized numbers of neuritic plaques, diffuse plaques, and NFT across five brain regions as described in [28] . Moreover, amyloid load was quantified as abundance of amyloid-β, labeled with a N-terminal directed monoclonal antibody, while PHFtau tangles, was quantified as the density of paired helical filament tau tangles.
We focused on the following aggregated neuropathological variables (Figure 1 and elsewhere) : a) "neuritic plaques" and "diffuse plaques" were defined as average of 5 scaled scores (namely scaled mid-frontal, temporal cortex, inferior parietal cortex, entorhinal cortex, and hippocampus plaques) [29, 30] . b) "NFT" measures the tangle average across 5 regions (mid-frontal cortex, mid-temporal cortex, inferior parietal cortex, entorhinal cortex, and hippocampus CA1) [29] . c) "Amyloid load" measures the overall amyloid load, which was defined as the mean amyloid scores across 8 regions (namely hippocampus entorhinal cortex, mid-frontal, inferior parietal cortex, anterior gyrus, calcarine cortex, cingulate regions, superior frontal gyrus) [29, 31, 32] . d)
Overall tangle score which reports the PHFtau tangle score across 8 regions (hippocampus, entorhinal cortex, midfrontal gyrus, inferior temporal, anterior gyrus, calcarine cortex. cingulate region, superior frontal gyrus).
DNA methylation data. DNAm was measured using the Illumina Infinium HumanMethylation450 BeadChip. The Illumina BeadChips measures bisulfite-conversionbased, single-CpG resolution DNA methylation levels at 485577 different CpG sites in the human genome. These data were generated by following the standard www.impactaging.com protocol of Illumina methylation assays, which quantifies methylation levels by the β value using the ratio of intensities between methylated and unmethylated alleles. Specifically, the β value is calculated from the intensity of the methylated (M corresponding to signal A) and un-methylated (U corresponding to signal B) alleles, as the ratio of fluorescent signals β = Max(M,0) / [Max(M,0) + Max(U,0) + 100]. Thus, β values range from 0 (completely un-methylated) to 1 (completely methylated) (Dunning, 2008). The DNA methylation data are available at the following webpage https://www.synapse.org/#!Synapse:syn3168763. We focused on brain samples of Caucasian subjects from ROS and MAP that include brain donation at the time of death (n=700) [12, 13] . Additional details on the DNA methylation data can be found in [9] .
Epigenetic clock analysis and DNAm age. Several recent studies have proposed to measure the age of tissue samples by combining the DNA methylation levels of multiple dinucleotide markers, known as Cytosine phosphate Guanines or CpGs [11, 33, 34] . In particular, the epigenetic clock based on 353 Cytosine phosphate Guanine (CpG) markers was developed to measure the age (known as "DNA methylation age" or "epigenetic age") of human tissues, organs and cell types-including brain, breast, kidney, liver, lung, blood [11] , and even applies to prenatal brain samples [35] . The epigenetic clock method -applied to two commercially standardized methylation platforms: the Illumina 450K array and the 27K arrays -is an attractive biomarker of aging because (1) it applies to most human tissues; (2) its accurate measurement of chronological age is unprecedented [11] ; (3) it is predictive of all-cause mortality even after adjusting for a variety of known risk factors [16] ; (4) it correlates with measures of cognitive and physical fitness in the elderly [17] ; (5) it has already been useful in detecting accelerated aging due to obesity [36] , Down syndrome [37] , Parkinson's disease [38] , and HIV infection [39] ; and . Further, the epigenetic clock was used to show that age acceleration of blood may predict the future onset of lung cancer [40] , that the cerebellum ages slowly [41] , that the blood of subjects with a severe developmental disorder ages normally [42] , and that semi-supercentenarians and their offspring age more slowly [47] .
Weighted DNAm measures across the 353 CpGs from the epigenetic clock were used to measure the DNAm age of DLPFC samples. These CpGs and their weights (coefficient values) were chosen in independent data sets by regressing chronological age on CpGs. DNAm age is then defined as predicted age, in years [43] .
Statistical analysis. Biweight midcorrelations and ordinary least squares regression models were used to examine whether postmortem neuropathology was associated with postmortem DNAm age in DLPFC, after controlling for age at death, study (ROS vs. MAP), and sex. For the bar plots in Figure 1 , we defined a grouping variable (high versus low) by dichotomizing the respective neuropathological variable according to the median value. The median was chosen in order to arrive at equal group sizes (high versus low) and to avoid overfitting due to the selection of an optimal threshold. Multivariate linear regression models were fit in the whole sample and in strata defined by AD dementia status (according to the clinical diagnosis). Here we did not use a linear mixed effects model since our dependent variable (DNAm age) is a time-invariant variable based on postmortem brain tissue. The linear models were used to determine whether GCF, WM, EM, SM, PO, and PS over all waves leading up to death were related to postmortem DNAm age in DLPFC. Standard errors for cognitive decline models were adjusted to account for multiple observations. These models also included potential confounders, such as age of clinical evaluation, age at death, study (ROS vs. MAP), and sex. Finally, step-wise linear models were run with DNAm age as the dependent variable and cognitive measures as the independent models. For these models we examined how the association between DNAm age and cognition was altered with the inclusion of either one or all of the neuropathology measure.
We report one-sided (one-tailed) p-values for the cognitive scores and neuropathology variables in our multivariate model analyses because our hypotheses involving cognitive scores are one-sided (e.g. that higher DNAm age is associated with worse cognitive functioning and higher levels of neuropathology).
Genetic analysis. Of the study samples, a total of 1102 individuals (632 normal/ 470 AD) were available with both genotypes and cognitive functioning or neuropathological measure. The GCTA software was used to estimate the heritability and genetic correlations based on both genotyped and imputed SNP markers. We used IMPUTE2 [44, 45] with haplotypes phased using SHAPEIT [46] to impute SNP and INDEL markers, with a reference panel based on the 1000 Genome haplotypes from 2,504 individuals (released in October 2014). As study individuals were genotyped on either Affymetrix SNP Array 6.0 or Illumina HumanOmniExpress, we performed imputation on each subset of individuals stratified by platform. We merged the imputation outputs across platforms and pruned in the markers with info measure > 0.4 in both sets. The other quality control was based on minor allele frequency (MAF) ≥ 0.02. We converted the IMPUTE2 output format to MaCH dosage format in order to use it as input for the GCTA software.
